The CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age !75 years, diabetes mellitus, previous stroke, vascular disease, age 65-74 years, female gender) score is used to estimate thromboembolic risk in atrial fibrillation (AF). Its usefulness in predicting in-stent restenosis (ISR) is unknown. We evaluated the predictive value of the CHA 2 DS 2 -VASc score in AF-free patients who have undergone stent implantation. A total of 1350 patients who underwent coronary angiography and successful bare-metal stent implantation were analyzed. The CHA 2 DS 2 -VASc score was calculated before percutaneous coronary intervention, and the association between the score and ISR was investigated. Patients (n ¼ 700; mean age: 61.4 [8.7] years, 63% men) were divided in 2 subgroups according to the presence of ISR; 265 of 700 patients had ISR. Mean CHA 2 DS 2 -VASc score was significantly higher in the ISR (þ) group than the ISR (À) group (3.7 [1.8] vs 2.1 [1.4], P < .001). According to multivariate logistic regression analysis, diabetes, hyperlipidemia, smoking, stent length, and CHA 2 DS 2 -VASc score were independent predictors of ISR. In conclusion, the CHA 2 DS 2 -VASc score may be useful as a new and simple tool to predict ISR.
Introduction
In-stent restenosis (ISR) is a major clinical problem and remains an unresolved issue in interventional cardiology era. 1 In spite of major improvements in stent materials, interventional techniques, and drug therapies, the incidence of ISR still ranges from 20.0% to 50.3% depending on clinical and procedural factors and the stent type implanted. 1 Several studies have been conducted to identify the reasons for ISR, and it was shown that clinical, lesion-related, procedural factors and patient-related factors are responsible for ISR. [2] [3] [4] Besides procedural problems related to percutaneous coronary intervention (PCI), chronic conditions related to increased inflammation such as heart failure, diabetes, hypertension, and stroke are also significant risk factors for ISR. 5, 6 The CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age !75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, female gender) score is used for embolic risk stratification in patients with atrial fibrillation (AF). 7 Recent studies have demonstrated that CHA 2 DS 2 -VASc score can predict adverse clinical outcomes in stable coronary artery disease (CAD) and acute coronary syndrome (ACS), irrespective of the presence of AF. 8, 9 The aim of this study was to evaluate the association of the preprocedure CHA 2 DS 2 -VASc score with ISR in patients who underwent PCI due to stable CAD.
Materials and Methods

Study Population
In this retrospective study, we analyzed patients who underwent successful bare-metal stent (BMS) implantation between January 2012 and December 2016. A total of 1350 patients who underwent coronary angiography and successful BMS implantation were screened for this study. Patients were excluded from the study if they had clinical evidence of malignancy (n ¼ 42), chronic inflammatory diseases (n ¼ 102), hepatic (n ¼ 95) or hemolytic disorders (n ¼ 32), end-stage kidney disease (n ¼ 84), rheumatologic diseases (n ¼ 31), thyroid hormone abnormalities (n ¼ 80) or any active infectious diseases (n ¼ 39), and AF (n ¼ 145). The remaining 700 patients were enrolled. The local ethics committee approved the study protocol.
Information on age, sex, presence of CAD risk factors (hypertension, diabetes, dyslipidemia, history of smoking, and family history), left ventricular ejection fraction (LVEF) before PCI, fasting blood glucose, and lipid profile values was recorded for each patient enrolled in the study. Hypertension was described as undergoing antihypertensive treatment with a diagnosis of hypertension. Low-density lipoprotein cholesterol levels above the target specified by European Society of Cardiology/European Society of Hypertension guidelines were categorized as dyslipidemia. 10 Diabetes was described as taking oral antidiabetics or insulin or follow-up fasting blood glucose levels fulfilling the American Diabetes Association's criteria. 11 Dyslipidemia was defined as taking lipid-lowering medication upon presentation. Also, stented vessels, time of clopidogrel administration before the procedure, time duration between clopidogrel administration and the procedure, and clopidogrel dosages were recorded. Length of stent and reason for stent implantation were also noted.
On the basis of the CHA 2 DS 2 -VASc score, patients were assigned 1 point for congestive heart failure, hypertension, age 65 to 74 years, diabetes mellitus, vascular disease, and female sex and 2 points for age 75 years or older and previous stroke. All patients had at least a score of 1, as all of them underwent PCI; thus, they had vascular atherosclerosis.
Coronary Angiography and Intervention
Patients underwent control angiography because of clinical indications, including high clinical suspicion of coronary stenosis or abnormal treadmill exercise test or myocardial perfusion scintigraphy. Coronary interventions were performed according to current practice guidelines and recorded in digital storage for further analysis. 12 The percentage of coronary stenosis was determined by 2 interventional cardiologists. If a patient had narrowing >50% in at least 1 major coronary artery, it was accepted as significant stenosis. Antiplatelet therapy, including 300 mg aspirin and 300 mg or 600 mg loading dose clopidogrel, was given to all patients before stent implantation. Unfractionated heparin determined by patient weight was administered at the beginning of the procedure. Activated clotting time routinely measured in all patients during coronary intervention to keep it >200 seconds. Femoral or radial technique was used based on physician's preference. A successful PCI was defined as achieving a minimum stenosis diameter reduction to <50% in the absence of any branch loss, dissection, or thrombus formation. 13 We also defined successful PCI as a reduction of stenosis diameter to <50% narrowing at final angiography.
14 Control coronary angiograms were performed via Judkins technique and interpreted by 2 independent cardiologists who were blinded to patient data. Stent restenosis rate was determined by visual assessment. Restenosis was defined as narrowing >50% in a stent area compared to normal diameter. Intraobserver variability was 96% and 97.5% and interobserver variability was 95% and 96% in a representative subset of 80 patients.
Laboratory Analysis
Venous blood samples were obtained from all patients for hematologic and biochemical measurements on admission just before the PCI. An automated complete blood count was obtained using a Coulter LH 780 Hematology Analyzer (Beckman Coulter Ireland Inc, Mervue, Galway, Ireland).
Statistical Analysis
All calculations were carried out using SPSS 22.0 "Statistical Package for Social Sciences" software (SPSS Inc, Chicago, Illinois). Continuous variables were presented as mean (standard deviation) or median (interval between quartiles); categorical variables were presented as percentages and numbers. Continuous variables were compared using Student t test or the Mann-Whitney U test, whereas categorical variables were compared using w 2 test or Fisher test. The relationship between the CHA 2 DS 2 -VASc score and other variables was analyzed using Spearman correlation. To explore the association between the variables and ISR, a simple logistic regression analysis was used, and variables with P < .10 were used in the multivariate logistic regression analysis. The results of regression analysis are presented as adjusted odds ratio and 95% confidence interval (CI). The predictive value of the CHA 2 DS 2 -VASc score in ISR was tested using receiver operating characteristic (ROC) analysis. A 2-sided P < .05 was considered significant.
Results
A total of 700 patients (mean age 61.4 [8.7] years, 63% men) were divided into 2 subgroups according to the presence of ISR; 265 of 700 patients had ISR. Table 1 presents the baseline characteristics of the study population. Compared to the ISR (À) group, patients in the ISR (þ) group had more diabetes, hyperlipidemia, cerebrovascular event history, heart failure, and they were more smokers. Mean CHA 2 DS 2 -VASc score was significantly higher in the ISR (þ) group than the ISR (À) group (3.7 [1.8] vs 2.1 [1.4], P < .001). The mean period between the 2 coronary angiographic studies for all study population was 14.2 (3.5) months.
There was significant positive correlation between CHA 2 DS 2 -VASc score and C-reactive protein (CRP) levels (r ¼ .384, P < .001). Table 2 presents the results of logistic regression analysis. Older age, diabetes, smoking, hyperlipidemia, LVEF, stent length, CRP, and CHA 2 DS 2 -VASc score reached statistical significance in univariable logistic regression analysis. When we put these variables into multivariable logistic regression analysis, diabetes, hyperlipidemia, smoking, stent length, and CHA 2 DS 2 -VASc score were found to be independent predictors of ISR. According to ROC analysis, a CHA 2 DS 2 -VASc score of at least 3 was predictive of ISR with 82% sensitivity and 76% specificity (area under curve ¼ 0.79, P < .001, 95% CI ¼ 0.71-0.86; Figure 1) .
Discussion
The present study demonstrated that the CHA 2 DS 2 -VASc score was independently associated with ISR in patients underwent coronary angiography for stable CAD.
Stent thrombosis and restenosis are the most common complications of stent implantation. Although stent thrombosis occurs nearly almost due to technical issues, stent restenosis occurs after serious inflammatory processes. 15 Through different mechanisms, both diabetes mellitus and arterial hypertension are associated with endothelial dysfunction and overexpression of several growth factors that promote muscle cell proliferation, the principal mechanism of lumen renarrowing after stent implantation. 16, 17 Chronic diseases such as diabetes mellitus, hypertension, and hyperlipidemia are related to increased inflammatory status of patients. 2 Moreover, it was demonstrated that many inflammatory and oxidative biomarkers including CRP, fibrinogen, lipoprotein(a), interleukin 6, and soluble CD40 ligand were related to angiographic restenosis after BMS implantation and inflammatory conditions.
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The Congestive heart failure, hypertension, Age > 75, diabetes mellitus, stroke (CHADS 2 ) and CHA 2 DS 2 -VASc scores were initially developed for stroke risk stratification in patients with AF. 7 Furthermore, recent research has extended the use of the CHA 2 DS 2 -VASc score to non-AF populations. The CHA 2 DS 2 -VASc score has been recently evaluated as a risk stratification tool for adverse cardiac events after PCI in patients without AF and was shown to have modest discrimination. Receiver operating characteristic curve for CHA2DS2-VASC score for predicting ISR. CHA2DS2-VASc indicates congestive heart failure, hypertension, age !75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, female gender; ISR, in-stent restenosis. Investigators reported that the CHADS 2 and CHA 2 DS 2 -VASc scores were associated with in-hospital and long-term adverse clinical outcomes, including mortality, in patients with both stable CAD and ACS. 23, 24 In patients evaluated for postmyocardial infarction risk, the CHADS 2 score was shown to have significant prognostic value for predicting atrial and ventricular arrhythmias that are associated with deterioration of heart failure and sudden cardiac death. 25 Kurtul and colleagues recently suggested that the CHA 2 DS 2 -VASc score !4 was independently associated with contrast-induced nephropathy after PCI for ACS treated by urgent PCI. 26 Likewise, in another recent study, CHA 2 DS 2 -VASc-hyperlipidemia, smoking (HS) score was positively correlated with the severity and complexity of CAD. It was also reported that CHA 2 DS 2 -VASc-HS was comparable to other risk scores for the risk stratification of the in-hospital major adverse cardiovascular events of patients with ACS. 24 Age, gender, hypertension, smoking, hyperlipidemia, and diabetes mellitus are the well-accepted major risk factors for CAD development. Several multivariable risk prediction algorithms incorporating major risk factors have been developed to assess the individual risk of developing atherosclerosis. [27] [28] [29] The CHA 2 DS 2 -VASc score, which is the combination of mentioned risk factors above, can also be used for risk stratification for patients undergoing stent implantation. Our study suggests that the CHA 2 DS 2 -VASc is a simple and comprehensive risk assessment score that provides an additional level of risk stratification beyond that provided by conventional risk scores in predicting ISR in patients undergoing revascularization with BMS. Because high CHA 2 DS 2 -VASc scores are associated with a higher risk of BMS ISR, patients with high CHA 2 DS 2 -VASc score undergoing stent implantations should be considered for drug-eluting stents and other measures to reduce ISR. Components of the CHA 2 DS 2 -VASc score are also risk factors for CAD and restenosis. Usefulness of this score rather than separate calculation of risk factors to predict ISR needs further larger studies that directly compares CHA 2 DS 2 -VASc score and other risk scores.
The results of our study should be interpreted in light of several limitations. First, the study was designed in a retrospective manner and represented a single-center experience with only BMS restenosis. Due to its design, we can only show association between clinical factors and restenosis and cannot find cause-effect relations. Second, the definition of ISR was based on visual assessment by subjective analysis by interventional cardiologists rather than more quantitative and informative intravascular ultrasound or optical computed tomographic results. Third, only patients treated with BMS were included in this study; however, today drug-elating stents are being used more frequently than BMS.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
